Celcuity Overview
- Year Founded
-
2012
- Status
-
Public
- Employees
-
155
- Stock Symbol
-
CELC
- Share Price
-
$56.31
- (As of Thursday Closing)
Celcuity General Information
Description
Celcuity Inc is a clinical-stage biotechnology company developing targeted therapies for multiple solid tumors. Its candidate, gedatolisib, is a kinase inhibitor of the PI3K/AKT/mTOR (PAM) pathway, binding all class I PI3K isoforms and mTORC1/2, offering comprehensive inhibition with a mechanism and pharmacokinetics differentiated from other therapies. The Phase 3 VIKTORIA-1 trial, evaluating gedatolisib with fulvestrant, with or without palbociclib, in HR+/HER2- breast cancer, has completed enrollment and reported results for PIK3CA WT tumors, with cohort 2 (PIK3CA MT) also enrolled. Phase 3 VIKTORIA-2 and Phase 1b/2 CELC-G-201 trials, evaluating combinations in endocrine-resistant HR+/HER2- breast cancer and metastatic castration-resistant prostate cancer, are ongoing.
Contact Information
Website
www.celcuity.comCorporate Office
- 16305 36th Avenue North
- Minneapolis, MN 55446
- United States
Corporate Office
- 16305 36th Avenue North
- Minneapolis, MN 55446
- United States
Celcuity Timeline
Celcuity Stock Performance
As of 19-Nov-2026, Celcuity’s stock price is $56.31. Its current market cap is $2.76B with 48.9M shares.
(As of Thursday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $56.31 | $55.59 | $53.54 - $151.02 | $2.76B | 48.9M | 1.25M | -$4.71 |
Celcuity Financials Summary
As of 30-Sep-2026, Celcuity has a trailing 12-month revenue of null.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 3,891,406 | 4,480,462 | 319,162 | 270,739 |
| Revenue | 0 | 0 | 0 | 0 |
| EBITDA | (254,406) | (172,025) | (113,137) | (66,088) |
| Net Income | (256,015) | (177,042) | (111,779) | (63,779) |
| Total Assets | 726,869 | 466,558 | 245,123 | 191,219 |
| Total Debt | 755,065 | 321,905 | 97,953 | 37,446 |
Celcuity Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Celcuity Comparisons
Industry
Financing
Details
Celcuity Competitors (2)
One of Celcuity’s 2 competitors is Molecular Express, a Corporation company based in Los Angeles, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Molecular Express | Corporation | Los Angeles, CA | ||||
| HiFiBiO Therapeutics | Venture Capital-Backed | Cambridge, MA |
Celcuity Patents
Celcuity Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20260053814-A1 | Treatment regimens for gedatolisib in hormonally-driven disorders | Pending | 21-Aug-2024 | ||
| WO-2026044119-A1 | Treatment regimens for gedatolisib in hormonally-driven disorders | Pending | 21-Aug-2024 | ||
| AU-2024398904-A1 | Treatment of ocular diseases using 1-(4-{[4-(dimethylamino)piperidin-1-yl]carbonyl)phenyl)-3-[4-(4,6- dimorpholin-4- yl-1,3,5-triazin-2-yl)phenyl]urea | Pending | 12-Dec-2023 | ||
| EP-4823581-A1 | Treatment of ocular diseases using 1-(4-{[4-(dimethylamino)piperidin-1-yl]carbonyl)phenyl)-3-[4-(4,6- dimorpholin-4- yl-1,3,5-triazin-2-yl)phenyl]urea | Pending | 12-Dec-2023 | ||
| WO-2025128712-A1 | Treatment of ocular diseases using 1-(4-{[4-(dimethylamino)piperidin-1-yl]carbonyl)phenyl)-3-[4-(4,6- dimorpholin-4- yl-1,3,5-triazin-2-yl)phenyl]urea | Inactive | 12-Dec-2023 | A61K31/5377 |
Celcuity Signals
Celcuity Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Celcuity ESG
Risk Overview
Risk Rating
Updated November, 08, 2026
37.85 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,592
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Biotechnology
Subindustry
of 431
Rank
Percentile
Celcuity FAQs
-
When was Celcuity founded?
Celcuity was founded in 2012.
-
Where is Celcuity headquartered?
Celcuity is headquartered in Minneapolis, MN.
-
What is the size of Celcuity?
Celcuity has 155 total employees.
-
What industry is Celcuity in?
Celcuity’s primary industry is Drug Discovery.
-
Is Celcuity a private or public company?
Celcuity is a Public company.
-
What is Celcuity’s stock symbol?
The ticker symbol for Celcuity is CELC.
-
What is the current stock price of Celcuity?
As of 19-Nov-2026 the stock price of Celcuity is $56.31.
-
What is the current market cap of Celcuity?
The current market capitalization of Celcuity is $2.76B.
-
Who are Celcuity’s competitors?
Molecular Express and HiFiBiO Therapeutics are competitors of Celcuity.
-
What is Celcuity’s annual earnings per share (EPS)?
Celcuity’s EPS for 12 months was -$4.71.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process